Abstract
The development of novel antitumor agents is paramount in the fight against drug resistance and its associated cardiotoxicity. The present study carried out a thorough anticancer evaluation of N- (4-oxo-2-(4-((5-aryl-1,3,4 thiadiazole-2yl) amino) phenyl thiazolidine-3-yl) benzamide (TH08) in Ehrlich ascites carcinoma (EAC) in Swiss albino mice. Our assessment included the measurement of tumor weight, the duration of survival for mice with tumors, and tumor cell growth inhibition. Additionally, we analyzed hematological parameters, like white and red blood cells and hemoglobin levels. The results we obtained clearly demonstrate that TH08 is a potent anticancer agent that exerts a positive effect on EAC cells. To determine TH08's effectiveness, We compared our findings to those achieved by using the standard medication, bleomycin. Our findings provide compelling evidence that TH08 has significant potential as a novel antitumor agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
